Pretax income is the income that a company earns before paying income taxes. Paratek Pharmaceuticals's pretax income for the
three
months ended in Jun. 2023 was €-13.4 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was €-59.9 Mil.
Paratek Pharmaceuticals's pretax margin was -38.10%.
During the past 13 years, Paratek Pharmaceuticals's highest Pretax Margin was -37.67%. The lowest was -391966.67%. And the median was -653.46%.
Paratek Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Paratek Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, Paratek Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paratek Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Paratek Pharmaceuticals's Pre-Tax Income falls into.
Paratek Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Paratek Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-59.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paratek Pharmaceuticals (FRA:N4CN) Pre-Tax Income Explanation
Paratek Pharmaceuticals's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as
During the past 13 years, Paratek Pharmaceuticals's highest Pretax Margin was -37.67%. The lowest was -391966.67%. And the median was -653.46%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paratek Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Paratek Pharmaceuticals (FRA:N4CN) Business Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:N4CN has been successfully added to your 